Adina Turcu, MD
Endocrinology, Diabetes & Metabolism · Ann Arbor, MINPI 1235314816
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,565 of the $4,887 with a category attached, or 93.4%. AstraZeneca accounts for 64.5% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $3,151, more than ten times the $125 reported in 2022.
Across 5 payments — averaging $977.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Astrazeneca UK Limited$2K
- Bayer$125
Across 3 payments — averaging $39,174 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$118K
What the payments were for
- Consulting fees$4,56593%
- Food & beverage$3227%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 3 | $3,151 |
| Astrazeneca UK Limited | 1 | $1,611 |
| Bayer | 1 | $125 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerendia$125
How this compares
$4,887 in reported general payments places this provider in the 65th percentile of 219 endocrinology, diabetes & metabolism providers in Michigan.
See all endocrinology, diabetes & metabolism providers in Michigan →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocortisone | 42 | $1,546 |
| Spironolactone | 22 | $532 |
| Levothyroxine Sodium | 26 | $421 |
Paid to pharmacies, not to this prescriber.
Other endocrinology, diabetes & metabolism in Ann Arbor
- Richard AuchusAnn Arbor$250K
- Elif OralAnn Arbor$81K
- Kenneth FeingoldAnn Arbor$43K
- William HermanAnn Arbor$42K
- Tobias ElseAnn Arbor$31K
- Amy RothbergAnn Arbor$29K
- Joanna Spencer-SegalAnn Arbor$24K
- Gary HammerAnn Arbor$15K
- Arash SoleimanpourAnn Arbor$14K
- Tae Hwa ChunAnn Arbor$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.